Literature DB >> 33952716

Prognostic and immunological potential of PPM1G in hepatocellular carcinoma.

Yi-Ren Lin1, Wen-Jing Yang2, Guo-Wang Yang1,2.   

Abstract

Liver hepatocellular carcinoma (LIHC) remains one of the most common causes of cancer death. Prior research suggested that the PPM1G gene is involved in LIHC. To explore the role of PPM1G in LIHC, we used several online databases. Expression profiling was performed via the Gene Expression Profiling Interactive Analysis (GEPIA), Hepatocellular Carcinoma Database (HCCDB), Oncomine and Human Protein Atlas (HPA) platforms. Mutation profiles were investigated via cBio Cancer Genomics Portal (cBioPortal). Survival analysis was performed via the Kaplan-Meier (KM) plotter and International Cancer Genome Consortium (ICGC) platforms. The biological function of PPM1G was analyzed via the Enrichr database. The influence of PPM1G expression in the tumor immune microenvironment was assessed via Tumor Immune Estimation Resource (TIMER). PPM1G expression was upregulated in various tumors, including LIHC. Overexpression of PPM1G was associated with poor prognosis in LIHC. PPM1G expression might be regulated by promoter methylation, copy number variations (CNVs) and kinases and correlate with immune infiltration. The gene ontology (GO) terms associated with high PPM1G expression were mRNA splicing and the cell cycle. The results suggest that PPM1G is correlated with the prognosis of LIHC patients and associated with the tumor immune microenvironment in LIHC.

Entities:  

Keywords:  PPM1G; hepatocellular carcinoma; immune infiltration; prognosis; spliceosome

Year:  2021        PMID: 33952716     DOI: 10.18632/aging.202964

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  2 in total

1.  Clinical Value of PPM1G Gene in Survival Prognosis and Immune Infiltration of Hepatocellular Carcinoma.

Authors:  Qingyu Xiao; Zhen Cheng; Wenbin Kuang; Haijun Wu; Xi Luo; Renling Wang
Journal:  Appl Bionics Biomech       Date:  2022-01-28       Impact factor: 1.781

2.  A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC.

Authors:  Xiang Liu; Jian Zeng; Huanyu Li; Feng Li; Bin Jiang; Ming Zhao; Zhuo Liu; Ruineng Li; Tiexiang Ma
Journal:  J Oncol       Date:  2022-06-28       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.